CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Defines coverage for measurement of serum drug levels and anti-drug antibodies to guide management of biologic therapies, primarily for members receiving anti-TNF agents and select biologics; applies to BlueCross BlueShield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionFor IBD patients, order drug and/or antibody concentration testing every 2 weeks for anti-TNF, vedolizumab, or ustekinumab to meet coverage criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Every 2 weeksCovered frequency for IBD

Not coveredNon-IBD testing

10Named drugs

6Procedure codes

Coverage Criteria and Limitations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and denials

Coverage determinations:

Covered for IBD: For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti-tumor necrosis factor (anti-TNF) therapies, vedolizumab therapy, or ustekinumab therapy MEETS COVERAGE CRITERIA.once every two weeks

applies to anti-TNF, vedolizumab, ustekinumab

Not covered for non-IBD inflammatory conditions: For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti-TNF therapies DOES NOT MEET COVERAGE CRITERIA.N/A

examples listed in policy

Not covered for other uses/drugs: For all other situations not addressed above, measurement of the serum drug levels and/or measurement of the antibodies to the drugs DOES NOT MEET COVERAGE CRITERIA for the following drugs (alone or as a combination test): adalimumab; certolizumab; etanercept; golimumab.N/A

explicit drug list in policy

Measurement of serum drug concentrations and/or anti-drug antibodies to guide biologic therapy is addressed as follows. For individuals with inflammatory bowel disease (IBD), testing for anti-TNF therapies, vedolizumab, or ustekinumab meets coverage criteria when performed once every two weeks. For all other situations not specifically covered for IBD, measurement of the serum drug level and/or antibodies to the drug does not meet coverage criteria for the listed products. The policy explicitly lists the following agents in its reimbursement and exclusion statements: adalimumab, certolizumab, etanercept, golimumab, infliximab (and infliximab biosimilars), rituximab, ustekinumab, and vedolizumab.

Drug and/or antibody concentration testing for anti-TNF therapies when used to treat conditions other than IBD (examples specifically cited in the policy include spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria and therefore will be denied under this policy. Additionally, outside the IBD-specific allowance, measurement of serum drug levels and/or antibodies does not meet coverage criteria for adalimumab, certolizumab, etanercept, golimumab, infliximab and its listed biosimilars, rituximab, ustekinumab, and vedolizumab.

Procedure and Billing Codes

Billing Rule

Coding and submission — billing guidance

Billing guidance: Report the most specific CPT/HCPCS code available. For proprietary assays (e.g., Procise ADL™), use the assigned CPT Category I/III or Proprietary codes (0514U, 0515U) when applicable; otherwise, report unlisted or miscellaneous codes (80299, 84999) only when no specific code exists. Ensure the claim includes documentation of the test name, manufacturer, method, and numeric result to support medical necessity and correct processing.

Include documentation of assay name, manufacturer (e.g., ProciseDx Inc.), and numeric result (µg/mL) with the claim.
Use 0514U for Procise ADL™ (adalimumab) quantitative assay when available; 0515U for infliximab quantitative assay.
Do not substitute unlisted codes (80299, 84999) if a specific CPT/HCPCS code exists.
Claims may require crosswalk justification when proprietary codes are billed; attach test method and clinical indication for benefit/regulatory alignment.

Provider Responsibilities and Authorization

Prior Authorization

Verify benefits and prior authorization before testing

Confirm benefit coverage and any prior authorization requirements before ordering or submitting claims for drug/antibody concentration testing; authorization requirements vary by the member's benefit plan.

Check the member's benefit at time of request to determine prior authorization and coverage applicability.
If proprietary codes (0514U/0515U) are used, ensure they match the test performed and the member's benefit rules.

Note

Align requests with member benefits and government regulations

Coverage decisions must align with the individual's benefits at the time of request and conform to applicable state and federal regulations (e.g., LCDs/NCDs); when government policy conflicts with this policy, the government policy governs.

Reference member benefits and applicable Medicare/Medicaid coverage determinations when submitting requests.
Follow state or federal requirements if they conflict with this policy.

Denial Risk

Denial risk: testing for non‑IBD indications

Requests for drug and/or antibody concentration testing for anti‑TNF therapies for conditions other than inflammatory bowel disease will be denied as not meeting coverage criteria.

Examples of non‑IBD conditions specified include spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
Testing for these indications is considered not medically necessary under this policy.

Clinical Background

Anti-drug antibodies are immune responses that can develop to therapeutic biologics and may reduce drug efficacy or contribute to loss of response. Therapeutic drug monitoring—measuring circulating drug concentrations and antibodies—has been proposed and studied particularly in IBD as a tool to manage loss of response and to guide dosing or switching of biologic therapy; however, the policy limits coverage of such testing primarily to IBD where evidence and clinical utility have been supported, and considers testing for many other indications not to meet coverage criteria.

Key Terms

Anti-drug antibodies — definition and clinical impact

DefinitionAntibodies developed by a patient against a therapeutic biologic that can diminish drug efficacy and promote adverse effects.

Clinical impact — loss of responseAnti-drug antibodies can contribute to loss of therapeutic response by neutralizing or increasing clearance of biologic agents, leading to reduced efficacy.

Clinical impact — adverse effectsThe presence of anti-drug antibodies may promote adverse effects.

Relevance to anti-TNF agentsAnti-drug antibodies are particularly relevant for targeted TNF inhibitors such as infliximab, adalimumab, etanercept, and golimumab.

Therapeutic drug monitoring (immunopharmacologic monitoring) — definition

DefinitionMeasurement of circulating drug concentrations and antibodies to the drug to manage loss of response and optimize biologic therapy.

PurposeIntended to detect anti-drug antibodies and subtherapeutic drug levels to guide dosing adjustments or switching of biologic therapy.

Context of useProposed primarily to manage loss of response in patients receiving biologic therapies, including anti-TNF agents for conditions such as IBD, RA, spondyloarthritis, and psoriasis.